Disclosure of Litigation Settlement Terms for Changzhou BrightGene Biomedical Co., Ltd.

Based on the public information obtained,

[1][2].

This case is a

. Aitanran sued BrightGene for unauthorized use of the “Ruisheng” logo as its functional skin care brand, which constitutes trademark infringement and unfair competition[1].

According to the public reply document to the listing review inquiry, the two parties

, with the main terms including[1][2]:

Settlement Terms	Specific Content
Settlement Amount	BrightGene shall pay a settlement amount of RMB 2.6 million to Aitanran
Waiver of Trademark Rights	Aitanran explicitly waives the right to pursue BrightGene’s use of the “Ruisheng” logo (including text, graphics, and combined forms) for its functional skin care brand prior to the signing of the agreement
Usage Restrictions	BrightGene shall not use the standalone “Ruisheng” logo on cosmetics
Restrictions on the Counterparty	Aitanran and its affiliates shall not use the standalone “Ruisheng” trademark/logo in the production, sales, or authorization of Class 3 goods (daily chemical products)

• BrightGene has accrued a provision for litigation of RMB 2.6337 million by the end of 2024
• The actual settlement payment is RMB 2.6 million, with a small difference from the accrued provision amount
• The settlement amount accounts for
  1.06%
  of the company’s net assets (RMB 282.3625 million), which will not have a material adverse impact on the company’s financial condition[1]

, the Shanghai Intellectual Property Court issued a Civil Ruling ((2025) Hu 73 Min Zhong No. 70), ruling:

• Revoke the civil judgment of the Fengxian District People’s Court of Shanghai ((2024) Hu 0120 Min Chu No. 17058)
• Approve Aitanran’s withdrawal of the lawsuit[1]

The litigation settlement matter has been disclosed through the following channels:

1. Risk factors section
   in the
   prospectus
2. Supplementary legal opinion
   issued by AllBright Law Office (Shanghai)
3. Reply document to the listing review inquiry letter
4. Brokerage listing sponsorship letter
   [1][2]

, and the disclosed content complies with securities regulatory requirements, covering core content such as the settlement amount, rights and obligations of both parties, and subsequent restriction clauses, which is of important reference value for investors’ decision-making.

---

[1] Supplementary Legal Opinion (II) of AllBright Law Office (Shanghai) on the Public Offering of Shares to Unspecified Qualified Investors by Changzhou BrightGene Biomedical Co., Ltd. and Its Listing on the Beijing Stock Exchange - Eastmoney.com (https://pdf.dfcfw.com/pdf/H2_AN202512021792591876_1.pdf)

[2] Reply to the Second Round of Review Inquiry Letter on the Application Documents for the Public Offering of Shares and Listing on the Beijing Stock Exchange by Changzhou BrightGene Biomedical Co., Ltd. - Eastmoney.com (https://pdf.dfcfw.com/pdf/H2_AN202512021792591872_1.pdf)